Herpetic Keratitis (HK) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Herpetic Keratitis (HK) Emerging Therapy and TPP Insights

Thelansis's "Herpetic Keratitis (HK) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Herpetic Keratitis (HK) Overview

Herpetic keratitis (HK) is a leading infectious cause of corneal blindness worldwide, caused predominantly by herpes simplex virus type 1 (HSV-1) - and less commonly HSV-2 - following primary ocular infection and subsequent latency establishment within the trigeminal ganglion, with recurrent reactivation driving progressive corneal damage. The pathophysiology involves both direct viral cytopathic injury to corneal epithelium and immune-mediated stromal inflammation, producing distinct clinical entities: epithelial keratitis - characterised by pathognomonic dendritic or geographic ulcers on fluorescein staining - stromal keratitis, endotheliitis, and neurotrophic keratopathy, each carrying distinct management implications. Patients present with unilateral eye pain, photophobia, lacrimation, blurred vision, and reduced corneal sensation - the latter a hallmark of herpetic aetiology. Diagnosis is primarily clinical, supported by slit-lamp biomicroscopy; PCR of corneal or aqueous samples confirms diagnosis in atypical presentations. Topical antivirals - ganciclovir gel or acyclovir ointment - are first-line for epithelial disease, while stromal keratitis requires judicious topical corticosteroids alongside antiviral cover to suppress immune-mediated injury. Oral acyclovir or valacyclovir prophylaxis significantly reduces recurrence frequency in patients with frequent relapses. Corneal transplantation addresses visually significant scarring in refractory cases. Prognosis worsens with recurrence frequency; long-term antiviral suppression, patient education regarding recurrence triggers, and regular ophthalmological surveillance are integral to preserving corneal integrity and visual function.

Key Highlights

• In China, incident cases of herpetic keratitis are projected to increase from approximately 206,184 in 2025 to nearly 221,717 by 2035, reflecting a growing disease burden.
• Recurrent HSV reactivation remains the primary driver of progressive corneal damage and vision impairment.
• Stromal keratitis and neurotrophic keratopathy continue to represent major causes of long-term visual morbidity.
• Long-term antiviral prophylaxis plays a critical role in reducing recurrence frequency and disease progression.
• Increasing awareness, earlier diagnosis, and improved ophthalmic management are supporting better disease outcomes.

Market Overview

• The China herpetic keratitis market is projected to grow from approximately $1,024.10 MN to $2,340.50 MN by 2035, reflecting substantial market expansion.
• Market growth is supported by:
• Increasing adoption of long-term antiviral suppression therapies
• Growing demand for advanced ophthalmic treatments for recurrent and severe disease
• Market value growth is driven by rising disease recurrence, prolonged treatment duration, and increased management of vision-threatening complications.
• Future market growth will depend on next-generation antiviral therapies, regenerative corneal treatments, and improved recurrence prevention strategies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country